Gryphon Therapeutics Inc.
http://www.gryphonrx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gryphon Therapeutics Inc.
SciClone CEO Friedhelm Blobel On Building A Specialty Pharma Business In China: An Interview With PharmAsia News (Part 2 of 2)
On the sidelines of the annual JP Morgan Healthcare Conference, Blobel talks about China price cuts, FCPA compliance, renegotiating promotional contracts with Sanofi, Pfizer and Baxter, and SciClone’s plans for in-licensing the next Zadaxin.
SciClone CEO Friedhelm Blobel On Building A Specialty Pharma Business In China: An Interview With PharmAsia News (Part 1 of 2)
On the sidelines of the annual JP Morgan Healthcare Conference, Blobel talks about China price cuts, FCPA compliance, renegotiating promotional contracts with Sanofi, Pfizer and Baxter, and SciClone’s plans for in-licensing the next Zadaxin.
Licensing Trends By Clinical Phase
We revisit a chart from 1997 examining deal volume by clinical phase to highlight the changing landscape of late stage licensing.
Roche Bucks the Trend, with Early-Stage Deals
Unlike many of its Big Pharma brethren, for Roche, preclinical and Phase I licensing has been a favored deal-making formula: collaborate with a small company on the development of a compound at or before clinical proof-of-concept, drive the program using its development expertise, and retain rights to follow-on products with which it can repeat the process, presumably having now lowered both compound and clinical risk. Its deal with Kosan is the latest example.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice